Literature DB >> 19917957

Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.

Neil Rajan1, James A A Langtry, Alan Ashworth, Catherine Roberts, Pam Chapman, John Burn, Alison H Trainer.   

Abstract

OBJECTIVES: To comprehensively ascertain the extent and severity of clinical features in affected individuals from 2 large families with proven heterozygous mutations in the CYLD locus and to correlate these findings with the 3 appendageal tumor predisposition syndromes (familial cylindromatosis, Brooke-Spiegler syndrome, and multiple familial trichoepitheliomas) known to be associated with such germline mutations.
DESIGN: Interfamilial and intrafamilial observational study.
SETTING: Tertiary genetic and dermatology referral center. PARTICIPANTS: Thirty-four individuals recruited from 2 large multigenerational families with CYLD mutations. Clinical details, history, and tumor maps were obtained from all participants; in 18, the information was corroborated by detailed clinical examination. MAIN OUTCOME MEASURES: Tumor density, distribution and histologic findings, associated medical conditions, patient symptoms, and impact of disease on quality of life.
RESULTS: The severity of penetrance and phenotype varied within families. Although an approximately equal female to male predisposition was noted, 5 women and 1 man (of 26 patients surveyed [23%]) had undergone total scalp removal. The average age at onset was 16 years (range, 8-30 years). Symptoms reported by affected patients included painful tumors (in 12 of 23 patients [52%] who answered the question), conductive deafness, and sexual dysfunction. Of the 26 surveyed patients, tumors were noted on the scalp in 21 (81%), on the trunk in 18 (69%), and in the pubic area in 11 (42%). Tumor mapping provided clinical evidence that correlated with hormonally stimulated hair follicles being particularly vulnerable to loss of heterozygosity and tumor induction.
CONCLUSIONS: The burden of disease at sites other than the head and neck appears to be underreported in the literature and greatly affects quality of life. Differentiation between the clinical diagnoses has little prognostic or clinical utility in genetic counseling, even within individuals from the same family. Thus, we suggest an encompassing diagnosis of "CYLD cutaneous syndrome." Finally, the clinical distribution of tumors suggests that hormonal factors may play an important role in tumor induction in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917957      PMCID: PMC2935681          DOI: 10.1001/archdermatol.2009.262

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  41 in total

1.  Characterization and isolation of stem cell-enriched human hair follicle bulge cells.

Authors:  Manabu Ohyama; Atsushi Terunuma; Christine L Tock; Michael F Radonovich; Cynthia A Pise-Masison; Steven B Hopping; John N Brady; Mark C Udey; Jonathan C Vogel
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

2.  Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice.

Authors:  Jun Zhang; Brigid Stirling; Stephane T Temmerman; Chi A Ma; Ivan J Fuss; Jonathan M J Derry; Ashish Jain
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

3.  Trichoepitheliomas and eccrine spiradenomas with spiradenoma/cylindroma overlap.

Authors:  Amy C Bumgardner; Sylvia Hsu; Janna K Nunez-Gussman; Mary R Schwartz
Journal:  Int J Dermatol       Date:  2005-05       Impact factor: 2.736

4.  CYLD mutations underlie Brooke-Spiegler, familial cylindromatosis, and multiple familial trichoepithelioma syndromes.

Authors:  A L Young; R Kellermayer; R Szigeti; A Tészás; S Azmi; J T Celebi
Journal:  Clin Genet       Date:  2006-09       Impact factor: 4.438

5.  Identification of the cylindromatosis tumor-suppressor gene responsible for multiple familial trichoepithelioma.

Authors:  Xue-Jun Zhang; Yan-Hua Liang; Ping-Ping He; Sen Yang; Hong-Yan Wang; Jian-Jun Chen; Wen-Tao Yuan; Shi-Jie Xu; Yong Cui; Wei Huang
Journal:  J Invest Dermatol       Date:  2004-03       Impact factor: 8.551

6.  Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.

Authors:  Thijn R Brummelkamp; Sebastian M B Nijman; Annette M G Dirac; René Bernards
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

7.  Dermal cylindroma (turban tumor). Case report.

Authors:  K Given; K Pickrell; D Smith
Journal:  Plast Reconstr Surg       Date:  1977-04       Impact factor: 4.730

8.  Sun exposure and basal cell carcinomas in the nevoid basal cell carcinoma syndrome.

Authors:  A M Goldstein; S J Bale; G L Peck; J J DiGiovanna
Journal:  J Am Acad Dermatol       Date:  1993-07       Impact factor: 11.527

9.  Multiple familial trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene.

Authors:  Aicha Salhi; Dorothea Bornholdt; Frank Oeffner; Sajid Malik; Ernest Heid; Rudolf Happle; Karl-Heinz Grzeschik
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  CYLD mutation causes multiple familial trichoepithelioma in three Chinese families.

Authors:  Guangyong Zheng; Landian Hu; Wei Huang; Kaide Chen; Xuejun Zhang; Sen Yang; Jianfang Sun; Yiqun Jiang; Guangbin Luo; Xiangyin Kong
Journal:  Hum Mutat       Date:  2004-04       Impact factor: 4.878

View more
  21 in total

1.  Enucleation of cylindromas in Brooke-Spiegler syndrome: a novel surgical technique.

Authors:  David Brass; Neil Rajan; James Langtry
Journal:  Dermatol Surg       Date:  2014-12       Impact factor: 3.398

2.  Multiple Facial Trichoepitheliomas and Vulval Cysts: Extending the Phenotypic Spectrum in CYLD Cutaneous Syndrome.

Authors:  Anna Dubois; Angel Alonso-Sanchez; Vrinda Bajaj; Akhtar Husain; Neil Rajan
Journal:  JAMA Dermatol       Date:  2017-08-01       Impact factor: 10.282

3.  Infiltrative recurrent eccrine spiradenoma of the anterior neck treated using Mohs micrographic surgery.

Authors:  Rajib R Rahim; Neil Rajan; James A A Langtry
Journal:  Dermatol Surg       Date:  2013-10-01       Impact factor: 3.398

4.  Epidermal CYLD inactivation sensitizes mice to the development of sebaceous and basaloid skin tumors.

Authors:  Yingai Jane Jin; Sally Wang; Joshua Cho; M Angelica Selim; Tim Wright; George Mosialos; Jennifer Y Zhang
Journal:  JCI Insight       Date:  2016-07-21

5.  CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.

Authors:  Paula Miliani de Marval; Shazia Lutfeali; Jane Y Jin; Benjamin Leshin; M Angelica Selim; Jennifer Y Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-04-08

6.  A mutational hotspot in CYLD causing cylindromas: a comparison of phenotypes arising in different genetic backgrounds.

Authors:  Nikoletta Nagy; Neil Rajan; Katalin Farkas; Agnes Kinyó; Lajos Kemény; Márta Széll
Journal:  Acta Derm Venereol       Date:  2013-11       Impact factor: 4.437

7.  A large family with CYLD cutaneous syndrome: medical genetics at the community level.

Authors:  Anderson Pontes Arruda; Augusto César Cardoso-Dos-Santos; Luiza Monteavaro Mariath; Mariléa Furtado Feira; Thayne Woycinck Kowalski; Kalina Ribeiro Fontenele Bezerra; Leonardo Augusto Coelho Torres da Silva; Erlane Marques Ribeiro; Lavinia Schuler-Faccini
Journal:  J Community Genet       Date:  2019-12-03

8.  The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling.

Authors:  Neil Rajan; Richard J R Elliott; Alice Smith; Naomi Sinclair; Sally Swift; Christopher J Lord; Alan Ashworth
Journal:  Oncotarget       Date:  2014-12-15

9.  Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.

Authors:  N Rajan; R Elliott; O Clewes; A Mackay; J S Reis-Filho; J Burn; J Langtry; M Sieber-Blum; C J Lord; A Ashworth
Journal:  Oncogene       Date:  2011-05-09       Impact factor: 9.867

10.  CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral sclerosis.

Authors:  Carol Dobson-Stone; Marianne Hallupp; Hamideh Shahheydari; Audrey M G Ragagnin; Zac Chatterton; Francine Carew-Jones; Claire E Shepherd; Holly Stefen; Esmeralda Paric; Thomas Fath; Elizabeth M Thompson; Peter Blumbergs; Cathy L Short; Colin D Field; Peter K Panegyres; Jane Hecker; Garth Nicholson; Alex D Shaw; Janice M Fullerton; Agnes A Luty; Peter R Schofield; William S Brooks; Neil Rajan; Mark F Bennett; Melanie Bahlo; John E Landers; Olivier Piguet; John R Hodges; Glenda M Halliday; Simon D Topp; Bradley N Smith; Christopher E Shaw; Emily McCann; Jennifer A Fifita; Kelly L Williams; Julie D Atkin; Ian P Blair; John B Kwok
Journal:  Brain       Date:  2020-03-01       Impact factor: 15.255

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.